<DOC>
	<DOCNO>NCT00674947</DOCNO>
	<brief_summary>Phase 1 , open-labeled , safety tolerability study treatment subject relapse refractory solid tumor .</brief_summary>
	<brief_title>A Phase I Study BIIB015 Relapsed/Refractory Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Age 18 year old time inform consent . Solid tumor relapse refractory least 1 prior anticancer systemic therapy standard therapy exist . ECOG Performance Status &lt; /= 2 . Exclusion Criteria History keratoconjunctivitis , open close angle glaucoma , `` dry eye '' disease . New York Heart Association ( NYHA ) Grade II great congestive heart failure . History myocardial infarction within 6 month prior Day 1 . Presence &gt; /= Grade 2 peripheral neuropathy . Known presence central nervous system brain metastasis . Prior therapy conjugate unconjugated maytansine derivative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>